The Scientific Board is one of the vital bodies of EU-IPFF.
The role of the Scientific Board includes:

Review publications
and documents

Support advocacy initiatives targeting the EU institutions

Help foster dialogue with medical societies, regulators and payers

Support publication in medical and specialised press

Scientific Advisory Board Members

Dr. Helmut Prosch
Medical University

unnamed (1).jpg

As. Prof. Natalia Stoeva MD, PhD
Acibadem City Clinic
Tokuda Hospital, Sofia

download (2).jpeg

Prof. Andreas Günther
University Hospital Giessen


Dr. Maria Molina
Health Universitat de
Barcelona Campus

download (1).jpeg

Dr. Alexander Simidchev

Prof. Wim Wuyts
University Hospital


Prof. Vincent Cottin


Prof. Demosthenes Bouros
National and Kapodistrian University of Athens


Bruno Crestani
Assistance Publique Hôpitaux de Paris


Dr. Claudia Valenzuela
Hospital La Princesa  
Comunidad de Madrid

download (1).jpeg

Dr. Katherine O'Reilly
Mater Misericordiae University Hospital, Dublin

Dr. Marlies Wijsenbeek
Erasmus Medisch Centrum Rotterdam


Dr. Helen Parfrey
Papworth Hospital


Cormac McCarthy
St. Vincent’s University Hospital and University College Dublin


Prof. Dr. Michael Kreuter
University of Heidelberg Germany


Dr. Francesco Bonella Ruhrlandklinik Medical Faculty
 University of Duisburg-Essen

Dr. Elisabetta Balestro
Azienda Ospedaliera di Padova,
Università degli Studi di Padova

Katarzyna Lewandowska.jpg

Dr. Katarzyna Lewandowska National Tuberculosis and Lung Diseases Research Institute Warsaw


Anne-Marie Russell
Imperial College London


Paolo Spagnolo
University of Padova, Italy

Research & Clinical Trials

Promoting and fostering idiopathic pulmonary fibrosis (IPF) research initiatives across Europe is one of the EU-IPFF’s core objectives. This includes engaging policy-makers in promoting research activities to find the cause and a cure for IPF, as well as initiatives to systematically involve patient organisations in clinical trial planning and development. 

Clinical trials are research studies to explore if an experimental treatment is safe and effective in treating a particular medical condition. Clinical trials are not possible without patient participation and are key to accelerating the development of new treatment options. The EU-IPFF Clinical Trial Finder is intended to inform patients about ongoing clinical trials and to help raise awareness of these studies. 

Use the new EU-IPFF Clinical Trial Finder to locate clinical trials near you. 


Some of the members of the Scientific Advisory Board took part in the establishment of the European IPF Charter and provided valuable insights into the medical background of some of the problems that IPF patients face. In addition, they were able to publish an extensive article about the creation of the IPF Charter in Europe’s most renowned scientific journal focused on lung diseases; The European Respiratory Journal. To view the abstract or download the article, please visit the ERS website

logo ePAG.png

The European Reference Network (ERN) aims to connect highly specialised healthcare professionals across EU Member States and to thereby improve access to diagnosis, treatment and provision of high quality healthcare for patients with rare diseases or conditions that require a concentration of resources, expertise and knowledge. ERN-LUNG (European Reference Network on Rare Pulmonary Diseases) covers a wide range of rare lung diseases and features a sub-group on interstitial lung diseases that also includes IPF. EU-IPFF works together with ERN-LUNG as an ePAG: an elected patient representatives who will ensure that the patient voice is heard throughout the ERN development process. The aim is to ensure that IPF diagnosis, care and treatment options is unified across Europe and that patients are able to live their lives to the fullest.

Relevant professional networks and organisations

Interdisciplinary ILD Network  

Interdisciplinary ILD Network